StockData
Advanced Biomed Inc. logo

Advanced Biomed Inc. (ADVB) company profile

ADVBNasdaqServices-Medical LaboratoriesFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$2.10−0.12 (-5.41%)

Close on Nov 17, 2026Market cap $3.47MP/E 0.4Yield –

About Advanced Biomed

Services-Medical Laboratories, SIC 8071

Advanced Biomed Inc. is a Nevada holding company that develops and operates FinTruth, an enterprise artificial intelligence financial verification platform. Following the divestment of its cancer research biomedical assets, the company focuses exclusively on AI technology applications. FinTruth evaluates AI-generated financial content, such as credit ratings, investment research, and financial reports, against source records and regulatory rules using a proprietary reasoning core. It offers numerical, logical, ontology, and narrative verification checks to generate auditable trails. The company targets enterprise clients, including commercial banks, securities firms, insurance carriers, asset managers, auditing practices, and financial technology companies.

The company delivers FinTruth through public cloud software-as-a-service, application programming interfaces, and on-premises deployments. Headquartered with primary engineering and research operations in Hong Kong, the firm employs 12 people across technical and administrative functions. It utilizes leased infrastructure from international cloud providers rather than owning physical data centers. The company also maintains a registered domain in the United States.

Summary of the business section of Advanced Biomed's latest annual report, written by StockData.

Company profile

Company

Legal name
Advanced Biomed Inc.
Founded
2014
Headquarters
Reno, NV
Address
401 Ryland St, Ste 200-A 89502
Phone
86-21-20510823
Website
advb.ai
Employees
12, Jun 30, 2026
Industry
Services-Medical Laboratories
Incorporated in
Nevada
Fiscal year ends
June 30
Auditor
WWC, P.C., San Mateo, California

Stock & identifiers

Ticker
ADVB
Exchange
Nasdaq
IPO date
Mar 6, 2025
Shares outstanding
2M, Oct 13, 2026
Public float
$2.70M, Dec 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-20 reverse, Feb 20, 2026
SEC CIK
1941029
CUSIP
00752P203
ISIN
US00752P2039
FIGI
BBG01HW4B3M4
Share class FIGI
BBG01HW4B3N3
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Advanced Biomed's leadership is listed in its proxy statement, last filed Jun 4, 2026.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryTotalvs. prior year
Mingze Yin
Director and Chief Financial Officer
$161.74K$161.74K–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 6, 2025
Securities offered
1,640,000
Exchange
Nasdaq
First trading day
Mar 6, 2025
First-day close
$3.65
Lock-up ends (est.)
Sep 2, 2025

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of the date of this Report, we had 12 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?